Patent Application
20070038060
The field of this invention is medical apparatus and procedures for imaging, identifying, and treating bodily tissues.
This application incorporates by reference essential information that is contained in Chang et al U.S. Pat. No. 6,535,625 issued Mar. 18, 2003; and Cerwin et al patent No. 6,974,415 issued Dec. 13, 2005, all in accordance with 37 C.F.R. 1.57(c).
It has long been known that cancer cells or lesions could be identified by their electrical conductivity. Later research indicates that within or bordering a cancerous tissue the electrical conductivity or impedance may vary (i.e., have a gradient). It is also known that acoustic power concentrated onto cancerous tissue will cause it to ablate or to be heated to destruction.
The Chang et al. and Cerwin et al. patents identified above describe a process referred to as “Electromagnetic Acoustic Imaging” (EMAI), in which electromagnetic signals are sent into bodily tissues under examination. Cancer cells or lesions along with some normal tissues are thereby activated to generate acoustic signals. These signals are then detected to identify the physical location of their sources. An important feature of the EMAI process is that the electric power densities of signals in the tissues during diagnostic procedures are within safe levels prescribed by federal agencies.
The present invention provides apparatus and methods with which electromagnetic signals are sent into the bodily tissue under examination, and acoustic or ultrasound signals developed from tissues containing conductivity gradients. Those signals may then be processed and used to send energy back into the bodily tissue under examination, for purpose of medical treatment.
Further according to the invention, acoustic or ultrasound signals induced from tissue may be phase adjusted, reflected from a time-reversal mirror and then applied simultaneously with a radio pulse so that the two wave actions interfere, constructively or destructively, at the source of induced ultrasound. Experimental or medical treatment purposes can thus be served with EMAI offering visual evidence of treatment effectiveness.
Also according to the invention, the time-reversed acoustic signals may be repetitively amplified, obtaining increased power to apply to the offending tissue.
Still further according to the invention, the applied electromagnetic signals may be generated as a series of pulses. The augmented images of the acoustic or ultrasound signals may be synchronized with still oncoming radio signals to be applied to tissues.
As another feature of the invention, the applied electromagnetic signals may be continued for a substantial period of time with controlled frequency modulation, (i.e., “chirping”), which gives rise to still other ways of selectively distinguishing or combining the two different types of energy signals.
The conceptual drawing of
This application incorporates by reference essential information from Fink U.S. Pat. No. 5,428,999 issued Jul. 4, 1995, and Berryman U.S. Pat. No. 6,755,083 issued Jun. 29, 2004, which describe the structure and operation of an ultrasonic time-reversal mirror assembly (TRM). According to the present invention the ultrasound signals induced from offending bodily tissues may be identified, amplified, and their directions reversed by a time-reversal mirror assembly before sending them back into some or all of the offending bodily tissues to provide medical treatment where needed.
Although not shown in the conceptual drawing itself, a complete system of apparatus needs to include a monitor for appropriate visual output of the information. Using the monitor a radiologist may select a region of interest which may include apparently abnormal or offending tissue, whether it be actual cancerous lesions, growths of veins or calcium deposits that surround cancerous tissue, blood vessels, or the like. In other words, a complete system of apparatus will provide the radiologist with ample opportunity to view possible targets in the region of interest and select one or more without involving adjacent tissue.
The system of apparatus includes a radio frequency signal generator which will generate radio waves at a known frequency f, within the range of about one-tenth to fifteen megahertz, which are then applied to bodily tissue through a known type of interface. In accordance with the EMAI process the electromagnetic energy received in the bodily tissue will induce ultrasound signals from tissues where conductivity gradients are found. The induced ultrasound signals will include a large component of energy at frequency 2f, double the frequency applied from the RF signal generator.
According to the invention the time-reversal mirror assembly, TRM, includes a sensor array of resonant filters for receiving the ultrasound signals and converting them into electronic form. In addition, the TRM also incorporates means for filtering and concentrating or amplifying those signals before reversing the direction of received ultrasound signals. The purpose of filtering is to more clearly identify the 2f energy component of the induced signals. The purpose of amplifying is to increase the energy level of the thus identified signals before applying them back to the bodily tissue for purpose of treatment. The filter and amplifier may be included as part of the TRM.
Auxiliary apparatus includes a synchronizer circuit to effectively control distributing, amplifying, and recombining pixel data generated by ultrasound signals received at the 2f frequency by the time-reversal mirror, as well as other associated signal processing requirements. Also included in the auxiliary equipment is an electromagnetic shield for protecting both the bodily tissue of a patient and sensitive instrumentation from uncontrolled or unwanted electrical signals.
The various parts of apparatus and bodily tissue shown in
In drawing
A complete time-reversal mirror apparatus includes not only the sensory array 11, but also an “N-Ply signal-summing memory” 46 and “Power amplifier” 44. Numeral 23 on the forward or right-hand surface of array11 indicates a window, which, with aid of an acoustic impedance matching transmission powder or gel, passes ultrasound signals to or from the patient's body. Within the patient region, arrows indicate the paths and directions of signals. Array 11 can be a linear array or 2D array.
Radio transmitter 40 whose output, when it gets through shield 21 at aperture 25 and into the patient's body, is within safe power density limits required by federal regulations. A pair of electrodes 16, coated with conductivity enhancing ointment, represents a means for applying the low-power density electromagnetic signals to the patient's body. Alternatively, the RF energy can be fed into the body by means of currents in a coil; the oscillating magnetic field produces a localized electric field. Numeral 1, indicates an early stage cancer, virtually invisible on this scale, and 2 indicates volumes within the patient's body where a large lesion or cancerous tissue may exist. Numeral 3 indicates capillaries, which convey blood from arterioles, as at numeral 15 and to a plexus as near 1 where blood-tissue exchanges occur. Numeral 4 indicates a venule. All three kinds of vessels are critical to growth of aggressive cancers and all three respond to EMAI probe radio signals, announcing their presence through induced ultrasound emission at frequency 2f.
Aperture 28 in shield 21 permits a bundle of N or fewer electrical or optical signal filaments to pass from array 11 into the N-ply signal-summing memory 46 depending upon the scanning protocol adopted. If no scanning is used, then each of the N transducers drives a single filament and stores data in a timed sequence of pixels in memory 46. This is the nearly pure TRM mode with time modeling distance away from array 11. The time difference between pixels along the t axis determines the TRM range resolution limit. The time difference must be no smaller than the time required for the resonant transducer elements to ring down after a received ultrasound signal stops. It is a common practice for ultrasound transducer arrays to have a band-width approximately equal to its central frequency. If, for example, f=1 MHz then the central frequency, 2f, of the transducers means that the minimum resolution distance is ˜0.5 μs or 0.3 mm at a sound speed of 1500 m/s. If linear scanning is used, then for a square array only √(N) signal filaments would be needed and √(N) lines could be sequentially stored. This would make phase differences between lines and so distort the reversed emissions of the TRM. The control circuitry could remove this relative time delay in reverse emission, but the total time delay would increase the minimum resolved distance of the TRM by the scanning time, T times the number of scans: T×√(N). A ganged pair of up to N electrical/optical switches 17 control both the path of signals coming from array 11 into the memory and also signals leaving the power amplifier to be supplied to the transducer array 11 through aperture 27. The latter signals will cause array 11 to produce acoustic signals from its right side, radiating them back to converge high intensity ultrasound onto the tissue portions of the patient's body from which they arose.
An important feature of the invention is that the apparatus may be used for repetitively converging ultrasound onto sources selected according to their distance, t, from the sensor array and their x, y positions transverse to the t-axis. That the t-axis position is selectable to within t±DF/2, where DF is the depth of field of the lens and TRM systems, results from the near-transparency of many tissue organs to ultrasound. This causes the poor ultrasound reflection of such organs. The pressure-adjustable focus of lens 33 allows t-axis scanning.
Monitor 19 can show the input signal surface at the sensor array when time t after a short radio pulse is within ±half the depth of field for a given lens f# setting. By changing the pressure in a vacuum hose, not shown connected to the acoustic lens 33, the focus is adjusted nearer to or farther from conductivity gradients to image some normal tissue/cancers. After orienting herself or himself to the image data, comparing it with normal ultrasound images, the radiologist could decide on treatment. If ablation or cell necrosis by ultrasound heating is chosen she could then erase from monitor 19 images of tissues not to be targeted. If the “water” region 35 and acoustic lens 33 are present, then a 2D image of a conductivity gradient may be displayed on monitor 19. Reversible lines 31 connect an image pixel on monitor 19 to the corresponding memory elements in the “N-Ply summation memory”. As the erasing proceeds in monitor 19, this connection, if enabled, erases the corresponding memory elements at t±half the depth of field. The remaining “N-Ply signal summing” memory should then be directed by “EMAI control circuitry” to input the “Power amplifier”. Alternating the pressure in the vacuum hose scans the t-axis. In this way, all memory elements for tissue to be protected can be removed from focused emissions of the “Power amplifier”. Settings of N-Ply switches 17 will be changed to permit high power irradiation for treatment. After a large pulse is sent to the targeted conductivity gradients, switches 17 will automatically revert to their previous settings and further radio bursts will be provided to re-image the region of interest so the effects of treatment can be viewed.
In conjunction with the time-reversal accrual and amplification of acoustic signals, a critical requirement is that the correct phase relationship must be preserved; that is, the signals must be “coherent”. (See definitions.) This is facilitated by an overall phase adjustment sent by EMAI control circuitry through aperture 30. Digital handling of the signals in the “N-Ply signal summing” and “Power amplifier” are more accurate than earlier analog signal processing. The sequence of accumulations results in the following accumulated signal strength:
where G is amplifier gain, r is gain reinforcement at the conductivity gradient, a is the attenuation coefficient for ultrasound signal travel through unit length of the patient's body and L is the distance from a particular gradient to the sensor array 11. If the factor combination Gr·e−2aL is close to unity as 1+epsilon where epsilon<<1 then
For large n, this resonance condition can be quite large, growing by 10000/s, so less than a minute should be needed to accumulate enough power to ablate a tumor or melt a capillary closed.
As an alternative to [0027] above, “Radio Transmitter” 14 may repetitively induce acoustic signals from conductive spots within the region of interest. This signal data would be accumulated in the summing memory, allowing examination with the included monitor 19. An image of conductive gradients will appear and strengthen. As data from acoustic enhancements also accumulate, images of organ boundaries will gradually overlay the gradient data, aiding localization of gradients within organs. The radiologist should decide whether to use the repetitively accumulated data for ablative ultrasound heat treatment of conductive tissue. If the distance between transducer array 11 and the farthest point of the region of interest is 15 cm then it would take 97 microseconds to collect all signals from the entire region of interest for each radio burst. Allowing 100 microseconds for the period between repetitive electromagnetic pulses would mean that in one second 10,000 samples could be acquired. This would increase the signal to noise ratio, S/N, by a factor of 100 and the amplitude of the memory data by 80 dB. This assumes that “Signal amplifier” gain cancels acoustic attenuation between organ boundaries and array 11.
In applying the method of the present invention to early stage detection of breast cancer, very little acoustic reflection may be obtained from cancerous tissue, but acoustic waves are nevertheless obtainable by electromagnetic acoustic induction.
In accordance with the invention after acoustic signals identifying the location of a tissue portion have been received, the application of electromagnetic signals may be discontinued and the acoustic signals then amplified in a continuing loop path between the tissue portion and the time-reversal mirror.
Obstructions may occur in such normal tissue as blood in capillaries or arterioles by abnormal tissues such as plaque accumulation, lesions or cancerous cells. Radiologists' experience should allow them to distinguish blood in normal vessels from abnormal tissue. Angiogenesis in breast tissue is taken as a sign that soon breast cancer may follow and the capillaries are targeted for ablation to prevent cancer growth. See
One conductivity enhanced electrode is placed on the patient's skin over a vessel close to the surface as, for instance, at the ankle. The other is placed over a blood vessel plexus close to the skin such as the cardiac plexus. These electrodes will capacitively couple to the blood, completing an alternating current circuit. The electric field will be small in the high conductivity normal blood in veins or arteries, but will increase at any obstruction like plaque accrual in a vessel. The conductivity gradient there will induce ultrasound emission. Running a simple ultrasound-to-audio transducer over the leg, for instance, by noting the position of the most intense ultrasonic emission at the double frequency 2f, may sense this obstruction which might then be viewed by using the invented apparatus near the site. Care should be taken to avoid dislodging the obstruction as a whole. Sufficient power should be used to vaporize it to prevent formation of a dangerous obstruction in a narrower vessel as in heart muscle or the brain.
This application claims priority of apparatus and methods disclosed in the following Provisional Application of Stephen A. Cerwin and David B. Chang, No. 60/689,216, filed Jun. 9, 2005, for “Method of Locating and Treating Cancer Using Electromagnetic Radiation, Induced Ultrasound Emissions, and Accumulated Time-Reversal of the Induced Ultrasound Emissions”.
| Number | Date | Country | |
|---|---|---|---|
| 60689216 | Jun 2005 | US |
